FAK/PYK2 promotes the Wnt/β-catenin pathway and intestinal tumorigenesis by phosphorylating GSK3β

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Aberrant Wnt/β-catenin signaling is a key driver of colorectal cancer (CRC).
• Developing effective Wnt pathway inhibitors for cancer therapy remains a significant challenge.
• Understanding novel regulatory mechanisms is crucial for identifying new therapeutic interventions.

Purpose of the Study:

• To elucidate a novel regulatory axis controlling Wnt/β-catenin signaling in colorectal cancer.
• To investigate the role of FAK and PYK2 in the aberrant activation of this pathway.
• To explore the potential of targeting this axis for CRC treatment.

Main Methods:

• Analysis of FAK and PYK2 expression in APC(min/+) mice adenomas and human CRC tissues.
• Investigation of the FAK/PYK2/GSK3β(Y216)/β-catenin signaling cascade.
• Assessment of pharmacological inhibition of FAK/PYK2 in a mouse model of intestinal tumorigenesis.

Main Results:

• FAK and PYK2 are elevated in adenomas and CRC tissues, functioning redundantly.
• FAK/PYK2 phosphorylate GSK3β(Y216), promoting β-catenin accumulation and intestinal tumorigenesis.
• Pharmacological inhibition of FAK/PYK2 reduced adenoma formation and key signaling molecules in vivo.

Conclusions:

• A novel FAK/PYK2/GSK3β(Y216)/β-catenin axis is identified as critical for Wnt/β-catenin pathway activation in APC-driven intestinal tumorigenesis.
• This axis represents a potential therapeutic target for colorectal cancer.
• Targeting FAK/PYK2 may offer a strategy to suppress Wnt-driven tumor initiation and progression.